Answers are grounded in this paper and cite their sources.
OBJECTIVE: To determine whether the 30-min C-peptide response during an oral glucose tolerance test (OGTT) is associated with incident cystic fibrosis-related diabetes (CFRD) in people with CF (pwCF) and normal glucose tolerance (NGT), for whom no risk-stratification tool exists. RESEARCH DESIGN AND METHODS: In this multicenter retrospective cohort study, 309 pwCF (age ≥8 years) from three Italian CF referral centers were followed for a median of 8.8 years (interquartile range [IQR] 7.4-17.3). Baseline OGTT-derived markers of β-cell function and insulin sensitivity were compared using time-varying Cox models adjusted for age, sex, BMI, forced expiratory volume in 1 s (% predicted), and modulator exposure, in the full cohort and a baseline NGT subgroup (n = 222), with bootstrap validation; an exploratory threshold was derived by grid search. RESULTS: CFRD developed in 70 of 309 pwCF (22.7%). OGTT categories and 120-min glucose showed the strongest discrimination. Among NGT pwCF, β-cell glucose sensitivity, 30-min insulin, 30-min C-peptide, and 60-min glucose were associated with CFRD; HOMA-insulin resistance and the Oral Glucose Insulin Sensitivity-120 index were not. Each IQR increase in 30-min C-peptide was associated with lower CFRD hazard (hazard ratio [HR] 0.52, 95% CI 0.30-0.92), robustly across specifications, although shrinkage suggested a smaller effect (HR 0.64-0.76). An exploratory 4.65 ng/mL (1.54 nmol/L) cutoff separated the two risk groups but was unstable under bootstrap resampling. Modulator exposure was associated with lower CFRD hazard (HR 0.27, 95% CI 0.08-0.89). CONCLUSIONS: Lower 30-min C-peptide is independently associated with incident CFRD in pwCF with NGT. Any risk threshold is exploratory and requires external validation before clinical use.
No takes yet. Share an insight, caveat, or question.
Foppiani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: